Medigene’s proprietary end-to-end platform enables the development of differentiated, best-in class T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Medigene develops these therapies on its own or in partnership.
- Discovery Stage
- CTA/IND-enabling
- Clinical Studies
Multiple Solid Tumor Types
NY-ESO-1 + PD1-41BB / HLA-A2
CTA / IND 2H 2024
Medigene’s lead candidate targeting NY-ESO-1 combined with our PD1-41BB costimulatory switch receptor.
Undisclosed Targets / Undisclosed HLAs + PD1-41BB
Lead selection 2H 2023
Generation of TCR T cells targeting appropriate antigens with several different HLA types each developed and improved with our optimization technologies and combined with our PD1-41BB costimulatory switch receptor.
PRAME / HLA-A2
Milestones set by BioNtech
Exclusively partnered with BioNtech. Also includes non-exclusive licenses to our optimization technologies
MAGE-A4 / HLA-A2
Milestones set by 2seventy bio
Exclusively partnered with 2seventy bio.
NY-ESO-1 / HLA-A2
Milestones set by Hongsheng Sciences
Exclusively partnered with Hongsheng Sciences.
Multiple Liquid Tumor Types
PRAME / HLA-A2
NY-ESO-1 / HLA-A2
Milestones set by Hongsheng Sciences
Exclusively partnered with Hongsheng Sciences.
Medigene’s Own Programs with Multiple Value Inflection Points
- Discovery
- Lead Candidate
- CTA/IND-enabling
- Clinical Studies
MDG1015
NY-ESO-1 / LAGE-1a
PD1-41BB
CTA / IND 2H 2024
Medigene’s lead candidate targeting NY-ESO-1 combined with our PD1-41BB costimulatory switch receptor.
MDG2011
KRAS G12V
PD1-41BB / CD40L-CD28
Lead selection Q3 2023
MDG2021
KRAS G12D
PD1-41BB / CD40L-CD28
Lead selection 1H 2024
MDG2012
KRAS G12V
PD1-41BB / CD40L-CD28
Lead selection 2024
MDG20XX
KRAS
PD1-41BB / CD40L-CD28
TBD
Medigene exploring additional multiple HLAs.
MDG10XX
undisclosed
undisclosed
TBD
Generation of TCR T cells targeting appropriate antigens with several different HLA types each developed and improved with our optimization technologies.
Multiple Partnerships Validate Potential Best-in-Class TCRs
- Discovery
- Lead Candidate
- CTA/IND-enabling
- Clinical Studies
PRAME
Yes
Set by BioNTech
Exclusively partnered with BioNtech. Also includes non-exclusive licenses to our optimization technologies
MAGE-A4
Yes*
Set by 2seventybio
Exclusively partnered with 2seventy bio.
NY-ESO-1
Yes
Set by Hongsheng Sciences
Exclusively partnered with Hongsheng Sciences.
MDG1011
PRAME
No
Partnering
NY-ESO-1
No
Set by Hongsheng Sciences
Exclusively partnered with Hongsheng Sciences.
- = Multiple Solid Tumor Types
- = Multiple Liquid Tumor Types
* Enhancement not licensed from Medigene
INTELLECTUAL PROPERTY
Medigene’s proprietary end-to-end platform for identifying, selecting and engineering best-in-class TCRs is protected by exclusively in-licensed and proprietary patents in Europe, North America and Japan. Patent rights individually protect all TCRs generated by our proprietary TCR platform technology in countries selected based on our corporate commercial long-term strategy. In addition, Medigene is constantly developing improved methods and technologies across our end-to-end platform to produce the best TCR therapies. These methods are also subject to new patent protection in line with our company’s patent strategy.